Roivant Sciences, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Basel Switzerland (2014)

Organization Overview

First Clinical Trial
2015
NCT02611921
First Marketed Drug
2017
desmopressin (ddavp)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ALYVANT | Dermavant Sciences, Chief Medical Officer | Dermavant Sciences GmbH | Dermavant Sciences, Inc. | ROIVANT